Published 6 issues per year
ISSN Print: 1045-4403
ISSN Online: 2162-6502
Indexed in
Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies
ABSTRACT
Coronaviruses (CoVs) are continuously emerging, highly transmissible, and pathogenic agents that primarily target the human respiratory system. Previous outbreaks of severe acute respiratory syndrome−CoV and Middle East respiratory syndrome−CoV remain life-threatening and global public health concerns. A novel CoV outbreak that occurred in December 2019 in Wuhan, China was declared a pandemic outbreak that has since killed millions of individuals worldwide. Rapid transmission, genetic variations, and unavailability of specific therapeutic drugs are major factors that led to this alarming and deadly situation. Currently, > 200 clinical vaccine trials are underway to combat infection. This review summarizes reports related to CoV origin, genetic variations, drug options, status of nine vaccines that were in phase III trials, and novel therapies including convalescent plasma and stem cell treatment.
-
Fung TS, Liu DX. Human coronavirus: Host-pathogen interaction. Ann Rev Microbiol. 2019;73:529-57.
-
Tang Q, Song Y, Shi M, Cheng Y, Zhang W, Xia X-Q. Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition. Sci Rep. 2015;5:17155.
-
Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai R, Teng JL, Tsang CC, Wang M. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995-4008.
-
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng C-TK, Wang Q, Du L, Tan W, Wilson IA. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5(4):eaav4580.
-
Xia S, Liu Q, Wang Q, Sun Z, Su S, Du L, Ying T, Lu L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014;194:200-10.
-
Wei J, Xu H, Xiong J, Shen Q, Fan B, Ye C, Dong W, Hu F. 2019 Novel coronavirus (COVID-19) pneumonia: Serial computed tomography findings. Kor J Radiol. 2020;21(4):501-4.
-
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Int Med. 2020;172(9):577-82.
-
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
-
McIntosh K. Coronaviruses: A comparative review. In: Arber W, Haas R, Henle W, Hofschneider PH, Jerne NK, Koldovsky P, Koprowski H, Maaloe O, Rott R, Schweiger HG, Sela M, Syruek L, Vogt PK, Wecker E, editors. Current topics in microbiology and immunology/Ergebnisse der mikrobiologie und immunitatsforschung. Vol. 63. Berlin, Heidelberg: Springer; 1974. p. 85-129.
-
Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502.
-
Tong S, Conrardy C, Ruone S, Kuzmin IV, Guo X, Tao Y, Niezgoda M, Haynes L, Agwanda B, Breiman RF. Detection of novel SARS-like and other coronaviruses in bats from Kenya. Emerg Infect Dis. 2009;15(3):482.
-
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181-92.
-
Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27(3):325-8.
-
Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Ped Infect Dis J. 2005; 24(11):S223-7.
-
de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS And MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523.
-
Luk HK, Li X, Fung J, Lau SK, Woo PC. Molecular epide-miology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019;71:21-30.
-
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med. 2020;382:727-33.
-
Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, Sun Z, Liu F, Wu K, Zhong B, Mei Y, Zhang W, Chen Y, Li Y, Shi M, Lan K, Liu Y. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect. 2020;9(1):313-9.
-
Phan T. Novel coronavirus: From discovery to clinical di-agnostics. Infect Genet Evol. 2020;79:104211.
-
van Doremalen N, Bushmaker T, Morris DH. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-7. PubMed PMID: 32182409.
-
Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. 2003 Dec;349(25):2431-41. PubMed PMID: 14681510. Epub 2003/12/19.eng.
-
Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-20.
-
Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.
-
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
-
Li Y, Xia L. Coronavirus disease 2019 (COVID-19): Role of chest CT in diagnosis and management. Am J Roentgenol. 2020;214(6):1280-6.
-
World Health Organization. Coronavirus; 2021. Available from: https://www.who.int/healthtopics/coronavirus#tab= tab_1.
-
Liu K, Chen Y, Lin R, Han K. Clinical feature of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-8.
-
Rothan HA, Byrareddy SN. The epidemiology and patho-genesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
-
Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 novel coro-navirus (2019-nCoV) pneumonia. Radiology. 2020;295(1): 200236.
-
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9.
-
Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci. 2004;101(12):4240-5.
-
Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci. 2009;106(14):5871-6.
-
Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci. 2014;111(42):15214-9.
-
Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18(2):290-301.
-
Perlman S, Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol. 2009;7(6):439-50.
-
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharmaceut Anal. 2020;10(2):102-8.
-
Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, Li S, Shan H, Jacobi A, Chung M. Chest CT findings in coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology. 2020;295(3):200463.
-
Wang Y, Kang H, Liu X, Tong Z. Combination ofRT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol. 2020;92(6):538-9.
-
Rainer TH, Chan PK, Ip M, Lee N, Hui DS, Smit D, Wu A, Ahuja AT, Tam JS, Sung JJ. The spectrum of severe acute respiratory syndrome-associated coronavirus infection. Ann Int Med. 2004;140(8):614-9.
-
Srinivas P, Sacha GL, Koval C. Antivirals for COVID-19. Cleve Clin J Med. 2020. doi: 10.3949/ccjm.87a.ccc030.
-
Blaising J, Polyak SJ, Pecheur E-I. Arbidol as a broad-spec-trum antiviral: An update. Antiviral Res. 2014;107:84-94.
-
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-36.
-
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Lui Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby FW, Zhang D, Wang C. A trial of lopinavir-ritonavir in adults hospi-talized with severe COVID-19. New Engl J Med. 2020 May;382(19)1787-99.
-
Hill A, Wang J, Levi J, Heath K, Fortunak J. Minimum costs to manufacture new treatments for COVID-19. J Virus Erad. 2020;6(2):61.
-
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: An old drug against today's diseases? Lancet Infect Dis. 2003;3(11):722-7.
-
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar;14(1):72-3.
-
Zhao H, Li T, Yao C, Gu Z, Liu C, Li J, Yang D. Dual roles of metal-organic frameworks as nanocarriers for miRNA delivery and adjuvants for chemodynamic therapy. ACS Appl Mater Interfaces. 2021;13(5):6034-42.
-
Brouwer PJ, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NM, Claireaux M, Kerster G. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643-50.
-
Quandt J, Holland RW, Chen Z, Veling H. The role of attention in explaining the no-go devaluation effect: Effects on appetitive food items. J Exper Psych Hum Percept Perform. 2019 Aug;45(8):1119.
-
Tanne JH. COVID-19: FDA panel votes to authorise Pfizer BioNTech vaccine. Br Med J. 2020 Dec 11;371:m4799. PubMed PMID: 33310748. Epub 2020/12/15.eng.
-
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schafer A, Ziwawo CT, DiPiazza AT. SARS-CoV-2 mRNA Vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567-71.
-
Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D, Kariko K. Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and in-crease resistance to cleavage by RNase L. Nucleic Acids Res. 2011;39(21):9329-38.
-
Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168(6):1114-25.
-
Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, Himansu S, Deterling J, Geilich BM, Ketova T, Mihai C, Lynn A, McFayden I, Moore MJ, Senn JJ, Stanton MG, Almarsson O, Ciaramella G, Brito LA. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1-11.
-
Ledford H. Moderna COVID vaccine becomes second to get US authorization. Nature News. 2020 [updated 2020 Dec 19]. Available at: https://www.nature.com/ articles/d41586-020-035937#:~:text=A%20week%20 after%20granting%20an,by%20Moderna%20of%20 Cambridge%2C%20Massachusetts.&text=In%20the%20 Umted%20States%2C%20the,prospect%20of%20a%20 tough%20winter.
-
Winslow RL, Milligan ID, Voysey M, Luhn K, Shukarev G, Douoguih M, Snape MD. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year. JAMA. 2017;317(10):1075-7.
-
Bos R, Rutten L, van der Lubbe JE, Bakkers MJ, Hardenberg G, Wegmann F, Zuijdgeest D, de Wilde AH, Koornneef A, Verwilligen A, van Manen D, Kwaks T, Vogels R, Dalebout TJ, Myeni SK, Kikkert M, Snijder EJ, Li Z, Barouch DH, Vellinga J, Langedijk JPM, Zahn RC, Custers J, Schuitemaker H. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5(91):1-11.
-
Tostanoski LH, Wegmann F, Martinot AJ, Loos C, McMahan K, Mercado NB, Yu J, Chan CN, Bondoc S, Starke CE. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med. 2020;26(11):1694-700.
-
Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583-8.
-
Mahase E. COVID-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant. Br Med J. 2020;371. doi: 10.1136/bmj.m3967.
-
Lu S. Heterologous prime-boost vaccination. Curr Op Immunol. 2009;21(3):346-51.
-
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-97.
-
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-54. PubMed PMID: 32450106. PMCID: Pmc7255193. Epub 2020/05/26.eng.
-
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
-
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
-
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.
-
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New Engl J Med. 2020;383(27):2603-15.
-
Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New Engl J Med. 2020;383(25):2427-38.
-
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ. An mRNA vaccine against SARS-CoV-2-Preliminary report. New Engl J Med. 2020;383:1920-31.
-
Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, Li J-X, Yang B-F, Wang L, Wang W-J. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-88.
-
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979-93.
-
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 Aug 15;396(10249):467-78. PubMed PMID: 32702298. PMCID: Pmc7445431. Epub 2020/07/24.eng.
-
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New Engl J Med. 2020;383(24):2320-32.
-
ClinicalTrials.gov [homepage on the Internet]. AZD1222 vaccine for the prevention of COVID-19 [accessed 2021 Feb 9; updated 2021 Feb 11]; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04540393.
-
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, Lytras S, Czudnochowski N, Shah R, Muery M, Jesudason N, De Marco A, Li K, Bassi J, Snell G. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184(5):1171-81.
-
Prup BM. Current state of the first COVID-19 vaccines. Vaccines. 2021;9(1):30.
-
Belete TM. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist. 2021;14:151.
-
Tandrup Schmidt S, Foged C, Korsholm KS, Rades T, Christensen D. Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators. Pharmaceutics. 2016 Mar;8(1):7. PubMed PMID: 26978390. PMCID: Pmc4810083. Epub 2016/03/16.eng.
-
Cortesi R, Esposito E, Corradini F, Sivieri E, Drechsler M, Rossi A, Scatturin A, Menegatti E. Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. Int J Pharmaceut. 2007 Jul 18;339(1-2):52-60. PubMed PMID: 17395411. Epub 2007/03/31.eng.
-
Khalaj-Hedayati A, Chua CLL, Smooker P, Lee KW. Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement. Influenza Other Respir Viruses. 2020 Jan;14(1):92-101. PubMed PMID: 31774251.
-
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA. 2020 Sep 8;324(10):951-60. PubMed PMID: 32789505. PMCID: PMC7426884.
-
Ols S, Yang L, Thompson EA, Pushparaj P, Tran K, Liang F, Lin A, Eriksson B, Hedestam GBK, Wyatt RT. Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity. Cell Rep. 2020;30(12):3964-71.
-
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 Jul 3;369(6499):77-81.
-
Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, Tang X, Carmona Porquera EM, Kalari KR, Kandimalla KK. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharmaceut. 2021 Mar 1;18(3):754-71. PubMed PMID: 33464914.
-
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. PubMed PMID: 32113510. PMCID: Pmc7128218. Epub 2020/03/03.eng.
-
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 Apr 28;323(16):1582-9. PubMed PMID: 32219428. PMCID: Pmc7101507. Epub 2020/03/29.eng.
-
Chen P, Nirula A, Heller B, Gottlieb RL. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England J Med. 2021 Jan 21;384(3):229-37. PubMed PMID: 33113295.
-
Scott LJ. Tocilizumab: A review in rheumatoid arthritis. Drugs. 2017 Nov;77(17):1865-79. PubMed PMID: 29094311. PMCID: PMC5736769.
-
Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. Int Immunopharmacol. 2020 Dec;89(Pt A):107018. PubMed PMID: 33045577. PMCID: Pmc7494278. Epub 2020/10/13.eng.
-
Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: The case for compassionate use. Pain Phys. 2020 Mar;23(2):E71-83. PubMed PMID: 32214286. Epub 2020/03/28.eng.
-
Watkins J. Preventing a COVID-19 pandemic. Br Med J. 2020;368. doi: 10.1136/bmj.m810.
-
Nadim SS, Ghosh I, Chattopadhyay J. Short-term predictions and prevention strategies for COVID-2019: A model based study. arXiv. 2020;arXiv:2003.08150.
-
Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
-
AYDEMİR Semih, ŞAHAN Ekrem, The role of ECG as a mortality predictor in COVID-19 patients treated in the intensive care unit, Journal of Health Sciences and Medicine, 4, 6, 2021. Crossref